FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:2489-2497 December 9, 2004 Number 24 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Thigpen, T. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background We evaluated the effect of adding secondary cytoreductive surgery to postoperative chemotherapy on progression-free survival and overall survival among patients who had advanced ovarian cancer and residual tumor exceeding 1 cm in diameter after primary surgery.

Methods Women were enrolled within six weeks after primary surgery. If, after three cycles of postoperative paclitaxel plus cisplatin, a patient had no evidence of progressive disease, she was randomly assigned to undergo secondary cytoreductive surgery followed by three more cycles of chemotherapy or three more cycles of chemotherapy alone.

Results We enrolled 550 women. After completing three cycles of postoperative chemotherapy, 216 eligible patients were randomly assigned to receive secondary surgical cytoreduction followed by chemotherapy and 208 to receive chemotherapy alone. Surgery was declined by or medically contraindicated in 15 patients who were assigned to secondary surgery (7 percent). As of March 2003, 296 patients had died and 82 had progressive disease. The likelihood of progression-free survival in the group assigned to secondary surgery plus chemotherapy, as compared with the chemotherapy-alone group, was 1.07 (95 percent confidence interval, 0.87 to 1.31; P=0.54), and the relative risk of death was 0.99 (95 percent confidence interval, 0.79 to 1.24; P=0.92).

Conclusions For patients with advanced ovarian carcinoma in whom primary cytoreductive surgery was considered to be maximal, the addition of secondary cytoreductive surgery to postoperative chemotherapy with paclitaxel plus cisplatin does not improve progression-free survival or overall survival.

Source Information

From Case Western Reserve University and the Division of Gynecologic Oncology, MetroHealth Medical Center — both in Cleveland (P.G.R.); the Department of Medicine, University of Connecticut, and Hartford Hospital — both in Hartford (S.N.); the Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, N.Y. (M.F.B.); the Division of Gynecologic Oncology, Duke University Medical Center, Durham, N.C. (D.C.-P.); the Division of Gynecologic Oncology, Pennsylvania State University, Hershey Medical Center, Hershey (G.O.); the Division of Gynecologic Oncology, University of Pennsylvania Cancer Center, Philadelphia (S.C.R.); the Division of Gynecologic Oncology, Indiana University School of Medicine, Indianapolis (D.H.M.); and UniPath and Colorado Gynecologic Oncology — both in Denver (J.M.S.).

Address reprint requests to Ms. Denise Mackey at the Gynecologic Oncology Group Administrative Office, 4 Penn Center, 1600 JFK Blvd., Suite 1020, Philadelphia, PA 19103.

Full Text of this Article

This article has been cited by other articles:

• Havrilesky, L. J., Alvarez Secord, A., Darcy, K. M., Armstrong, D. K., Kulasingam, S. (2008). Cost Effectiveness of Intraperitoneal Compared With Intravenous Chemotherapy for Women With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. JCO 26: 4144-4150 [Abstract] [Full Text]  
• Winter, W. E. III, Maxwell, G. L., Tian, C., Sundborg, M. J., Rose, G. S., Rose, P. G., Rubin, S. C., Muggia, F., McGuire, W. P. (2008). Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. JCO 26: 83-89 [Abstract] [Full Text]  
• Spriggs, D. R., Brady, M. F., Vaccarello, L., Clarke-Pearson, D. L., Burger, R. A., Mannel, R., Boggess, J. F., Lee, R. B., Hanly, M. (2007). Phase III Randomized Trial of Intravenous Cisplatin Plus a 24- or 96-Hour Infusion of Paclitaxel in Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. JCO 25: 4466-4471 [Abstract] [Full Text]  
• Markman, M. (2007). Concept of Optimal Surgical Cytoreduction in Advanced Ovarian Cancer: A Brief Critique and a Call for Action. JCO 25: 4168-4170 [Full Text]  
• Winter, W. E. III, Maxwell, G. L., Tian, C., Carlson, J. W., Ozols, R. F., Rose, P. G., Markman, M., Armstrong, D. K., Muggia, F., McGuire, W. P. (2007). Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. JCO 25: 3621-3627 [Abstract] [Full Text]  
• Darcy, K. M., Tian, C., Reed, E. (2007). A Gynecologic Oncology Group Study of Platinum-DNA Adducts and Excision Repair Cross-Complementation Group 1 Expression in Optimal, Stage III Epithelial Ovarian Cancer Treated with Platinum-Taxane Chemotherapy. Cancer Res. 67: 4474-4481 [Abstract] [Full Text]  
• Harter, P., du Bois, A., Hahmann, M., Hasenburg, A., Burges, A., Loibl, S., Gropp, M., Huober, J., Fink, D., Schroder, W., Muenstedt, K., Schmalfeldt, B., Emons, G., Pfisterer, J., Wollschlaeger, K., Meerpohl, H.-G., Breitbach, G.-P., Tanner, B., Sehouli, J., for the Arbeitsgemeinschaft Gynaekologische Onkolo, (2006). Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Ann. Surg. Oncol. 13: 1702-1710 [Abstract] [Full Text]  
• Gervais, D. A., Arellano, R. S., Mueller, P. R. (2006). Percutaneous radiofrequency ablation of ovarian cancer metastasis to the liver: indications, outcomes, and role in patient management.. Am. J. Roentgenol. 187: 746-750 [Abstract] [Full Text]  
• Bhoola, S., Hoskins, W. J. (2006). Diagnosis and management of epithelial ovarian cancer.. Obstet Gynecol 107: 1399-1410 [Abstract] [Full Text]  
• Wenzel, L., Huang, H. Q., Monk, B. J., Rose, P. G., Cella, D. (2005). Quality-of-Life Comparisons in a Randomized Trial of Interval Secondary Cytoreduction in Advanced Ovarian Carcinoma: A Gynecologic Oncology Group Study. JCO 23: 5605-5612 [Abstract] [Full Text]  
• (2005). Is Second-Look Surgery Useful in Advanced Ovarian Cancer?. JWatch Women's Health 2005: 2-2 [Full Text]  
• Cannistra, S. A. (2004). Cancer of the Ovary. NEJM 351: 2519-2529 [Full Text]  
• Penson, R. T., Sahani, D., Bell, D. A. (2004). Case 37-2004 - A 52-Year-Old Woman with Postmenopausal Bleeding and a Cystic Ovarian Mass. NEJM 351: 2531-2538 [Full Text]  
• Thigpen, T. (2004). The If and When of Surgical Debulking for Ovarian Carcinoma. NEJM 351: 2544-2546 [Full Text]